NCT06208826View on ClinicalTrials.gov

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2028

Conditions
Head and Neck Cancer
Interventions
DRUG

Toripalimab

Toripamab, IV, 240mg, every 3 weeks for 15 cycles

RADIATION

Radiation Therapy

Radiation Therapy

DRUG

Cisplatin

Chemotherapy agent

Trial Locations (1)

300000

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER